Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: An observational study and review of the literature

Journal of Hospital Medicine

Volumn 5, Issue 1, 2010, Pages

  Abougergi, Marwan S ^a   Broor, Apoorv ^b   Cui, Wei ^c   Jaar, Bernard G ^d,e,f  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b Wheaton Franciscan Healthcare St Joseph's Hospital   (United States)

^c GOOD SAMARITAN HOSPITAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEPHROLOGY CENTER OF MARYLAND   (United States)

Author keywords

Clostridium difficile; Diarrhea; Immunity; Immunoglobulin; Nosocomial infection

Indexed keywords

CEFAZOLIN; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN; COLESTYRAMINE; IMMUNOGLOBULIN; LEVOFLOXACIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; INFECTION RISK; LENGTH OF STAY; LUNG EDEMA; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; COLITIS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALS, TEACHING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MEDICAL AUDIT; MIDDLE AGED; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 74949110785     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.542     Document Type: Article

References (48)

1. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis. 2004;189:1585-1589.
2. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363-372.
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
4. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466-472.
5. Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by Clostridium difficile. Infect Immun. 1981;34:1036-1043.
6. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
7. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994;62:384-389.
8. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162:678-684.
9. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38:350-354.
10. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
11. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol. 2004;38:414-418.
12. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5: 549-557.
13. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586-1590.
14. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-1597.
15. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991; 118:633-637.
16. Warny M, Denie C, Delmee M, Lefebvre C. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg. 1995;50: 36-39.
17. Hassett J, Meyers S, McFarland L, Mulligan ME. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis. 1995;20(suppl 2):S266-S268.
18. Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut. 2002;51:456.
19. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53:882-884.
20. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing. 2006;35:85-86.
21. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640-645.
22. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41:366-370.
23. Chandrasekar T, Naqvi1 N, Waddington A, et. al. Intravenous immunoglobulin therapy for refractory Clostridium difficile toxin colitis in chronic kidney disease: case reports and literature review. NDT Plus. 2008;1: 20-22.
24. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriatr Pharmacother. 2007;5:48-51.
25. Juang PS, Skledar J, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control. 2007;35:131-137.
26. Koulaouzidis A, Tatham R, Moschos J, Tan CW. Successful treatment of Clostridium difficile colitis with intravenous immunoglobulin. J Gastrointestin Liver Dis. 2008;17:353-359.
27. Cone LA, Lopez C, Tarleton HL, et al. A durable response to relapsing Clostridium difficile colitis may require combined therapy with high-dose oral Vancomycin and intravenous immune globulin. Infect Dis Clin Pract. 2006;14:217-220.
28. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
29. Ash L, Baker ME, O'Malley CM Jr, Gordon SM, Delaney CP, Obuchowski NA. Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. AJR Am J Roentgenol. 2006;186:1393-1400.
30. Andrews CN, Raboud J, Kassen BO, Enns R. Clostridium difficile-associated diarrhea: predictors of severity in patients presenting to the emergency department. Can J Gastroenterol. 2003;17:369-373.
31. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245: 267-272.
32. Moshkowitz M, Ben-Baruch E, Kline Z et al. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis. 2007;9:173-177.
33. Ramaswamy R, Grover H, Corpuz M, Daniels P, Pitchumoni CS. Prognostic criteria in Clostridium difficile colitis. Am J Gastroenterol. 1996;91: 460-464.
34. Castagliuolo I, Keates AC, Wang C, et al. Clostridium difficile toxin a stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol. 1998;160:6039-6045.
35. Castagliuolo I, Keates AC, Qiu B, et al. Increased substance P responses in dorsal root ganglia, intestinal macrophages during Clostridium difficile toxin a enteritis in rats. Proc Natl Acad Sci U S A. 1997;94:4788-4793.
36. Flegel WA, Müller F, Däubener W, Fischer HG, Hadding U, Northoff H. Cytokine response by human monocytes to Clostridium difficile toxin a and toxin B. Infect Immun. 1991;59:3659-3666.
37. Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol. 1998;47:591-598.
38. Bacon AE, 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis. 1994;18:205-209.
39. Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983;148:93-100.
40. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74:6339-6347.
41. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985;13:97-101.
42. Vernet A, Corthier G, Dubos-Ramare F, Parodi AL. Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice. Infect Immun. 1989;57:2123-2127.
43. Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun. 1991;59:1192-1195.
44. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis. 1992;166:1287-1294.
45. Ghose C, Kalsy A, Sheikh A, et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun. 2007;75:2826-2832.
46. Giannasca PJ, Zhang ZX, Lei WD, et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun. 1999;67:527-538.
47. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 1992;102:35-40.
48. Johnson S, Sypura WD, Gerding DN, Ewing SL, Janoff EN. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun. 1995;63:3166-3173.